Drugs / Interferon alfa-n3
Interferon alfa-n3
also known as
Alferon LDO · .alpha.-interferons · Alferon · Alferon n · IFN-An3 · Interferon alpha-n3 · Leukocyte interferon
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ALFERON N INJECTION | — | 1989-10-10 | fda.gov ↗ |
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00002078 | — | HIV infectious disease | Purdue Frederick | Completed | No outcome recorded |
| Phase not applicable3 trials · 1 missed | ||||||
| — | NCT00002018 | — | HIV infectious disease | Interferon Sciences | Completed | No outcome recorded |
| — | NCT00000844 | ? → Jun 2002 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| — | NCT00002012 | — | HIV infectious disease | Interferon Sciences | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00215826 Comparator | Nov 2004 → Apr 2006 | severe acute respiratory syndrome | AIM ImmunoTech Inc. | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon alfa-n3 | “orally administered low dose interferon alfa-n3 as an antiviral and immunomodulator” NCT00215826 ↗ |
| Known as | .alpha.-interferons | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109047 ↗ |
| Known as | Alferon | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109047 ↗ |
| Known as | Alferon LDO | “Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects” NCT00002018 ↗1“Alferon® LDO (natural interferon alfa-n3)” NCT00215826 ↗ |
| Known as | Alferon n | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109047 ↗ |
| Known as | IFN-An3 | “To conduct a double-blind, randomized, dose ranging study of an orally administered low dose interferon alfa-n3 (IFN-An3) immunomodulator in the treatment of symptomatic HIV+ subjects.” NCT00002018 ↗ |
| Known as | Interferon alpha-n3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109047 ↗ |
| Known as | Leukocyte interferon | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109047 ↗ |
| Action | Activate | “determine an Alferon LDO dose level that increases or upregulates genes known to be mediators of interferon response” NCT00215826 ↗ |
| Modality | Protein / enzyme biologic | “low-dose oral alpha-interferon (alpha-IFN)” PMID 10634196 ↗ Dec 1999 |
| Route | Oral | “low-dose oral alpha-interferon (alpha-IFN)” PMID 10634196 ↗ Dec 1999 |